Education
About Us
Working with TipRanks
Follow Us
ImageneBio (IMA)
NASDAQ:IMA
IMA Stock Chart & Stats
$8.61
--
Market closed
$8.61
--
Day’s Range― - ―
52-Week Range$7.24 - $23.28
Previous CloseN/A
VolumeN/A
Average Volume (3M)69.52K
Market Cap
$92.14M
Enterprise Value-$25.30M
Total Cash (Recent Filing)$95.64M
Total Debt (Recent Filing)$5.68M
Price to Earnings (P/E)―
Beta0.85
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,181,676
10 Day Avg. Volume58,561
30 Day Avg. Volume69,515
Financial Highlights & Ratios
PEG Ratio0.52
Price to Book (P/B)7.54
Price to Sales (P/S)0.00
P/FCF Ratio-20.64
Enterprise Value/Market Cap-0.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-538.28
Enterprise Value/Ebitda0.71
Forecast
1Y Price Target
$30.00Price Target Upside248.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Corporate MergerThe merger with Inmagene Biopharmaceuticals is expected to provide the combined company with an estimated $175 million in cash to support development of the anti-OX40 antibody, IMG-007.
Market PotentialThere is a blockbuster opportunity for IMG-007 in atopic dermatitis and longer-term potential in additional inflammatory and immunological indications.
Product DevelopmentIMG-007 has shown comparable efficacy to other OX40 therapies in development in atopic dermatitis, with a more favorable safety profile due to its non–T-cell-depleting design.
Bears Say
Clinical TrialsSanofi shared preliminary Phase II results with amlitelimab, an OX40L antibody, where the primary endpoint was not met at the highest dose level.
Ownership And ValuationFollowing the merger, current Ikena shareholders will own approximately 34.8% of the combined company, suggesting a combined company value of less than $300 million and enterprise value of below $120 million.
ImageneBio News
IMA FAQ
What was ImageneBio’s price range in the past 12 months?
ImageneBio lowest stock price was $7.24 and its highest was $23.28 in the past 12 months.
What is ImageneBio’s market cap?
ImageneBio’s market cap is $92.14M.
When is ImageneBio’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were ImageneBio’s earnings last quarter?
ImageneBio released its earnings results on Aug 07, 2025. The company reported -$0.688 earnings per share for the quarter, missing the consensus estimate of -$0.33 by -$0.358.
Is ImageneBio overvalued?
According to Wall Street analysts ImageneBio’s price is currently Undervalued.
Does ImageneBio pay dividends?
ImageneBio does not currently pay dividends.
What is ImageneBio’s EPS estimate?
ImageneBio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImageneBio have?
ImageneBio has 11,181,676 shares outstanding.
What happened to ImageneBio’s price movement after its last earnings report?
ImageneBio reported an EPS of -$0.688 in its last earnings report, missing expectations of -$0.33. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of ImageneBio?
Currently, no hedge funds are holding shares in IMA
ImageneBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.25%
12-Months-Change
Fundamentals
Return on Equity
-23.76%
Trailing 12-Months
Asset Growth
-19.89%
Trailing 12-Months
Company Description
ImageneBio
Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis
IMA Stock 12 Month Forecast
Average Price Target
$30.00
▲(248.43% Upside)
Technical Analysis
Ownership Overview
30.26% Insiders
0.53% Mutual Funds
― Other Institutional Investors
67.19% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---